Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 27.25p 26.50p 28.00p 27.25p 27.25p 27.25p 3,202,335.00 07:37:13
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 48.5 -12.1 -2.3 - 161.90

Allergy Therapeutics Share Discussion Threads

Showing 3351 to 3374 of 3375 messages
Chat Pages: 135  134  133  132  131  130  129  128  127  126  125  124  Older
DateSubjectAuthorDiscuss
28/4/2017
13:55
3m sell! at 27p - could this be the reason for the stall in the price?
richsawko
25/4/2017
17:34
Jiggery pokey going today, on with our coiled spring.
jimmyloser
19/4/2017
09:47
So potential competition have ceased study - could be very positive for AGY
richsawko
19/4/2017
09:39
Meanwhile, news from Circassia, one of Neil Woodford's investments: Oxford, UK - 18 April 2017: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces top-line results from its investigational house dust mite allergy immunotherapy phase IIb field study. In the study, both the active treatment and placebo greatly reduced subjects' allergy symptoms and rescue medication use. As a result, the treatment did not show a significant effect compared with placebo and the study did not meet its primary endpoint. The results show the immunotherapy was well tolerated with a highly favourable safety profile. Steve Harris, Circassia's Chief Executive, said: "We are naturally disappointed by this outcome, which is in line with our cat allergy phase III study where there was also a very marked placebo effect. Although subjects receiving the immunotherapies in both these studies had greatly improved allergy symptoms, the strong placebo effect made it highly challenging to achieve the studies' endpoints." "It is concerning that in two well-designed field trials, a robust placebo response has confounded our ability to demonstrate a significant treatment effect, despite positive results in earlier chamber studies. We remain convinced that the technology has biologic activity, but we also believe the difficulty in overcoming the placebo effect using the field study designs required by regulators represents a significant hurdle, and consequently we will make no further investment in our allergy portfolio. As indicated previously, we will now focus on our wider respiratory business, in particular our new US commercial collaboration with AstraZeneca, our market-leading NIOX(R) franchise and the development of our broader respiratory portfolio." Next steps Following the receipt of disappointing cat allergy phase III results in June last year, Circassia halted significant new investment in its allergy portfolio while awaiting the outcome of its house dust mite field study. Following these new results, Circassia will make no further investment in its allergy programmes.
lordshaw
18/4/2017
15:05
Aborted take off.
shauney2
12/4/2017
15:55
Looks like they have carried him off and its away.
shauney2
12/4/2017
12:03
Lets hope it doesn't turn into a United Airlines flight.
shauney2
12/4/2017
11:55
At the gate and awaiting takeoff!
jimmyloser
10/4/2017
17:27
Looks like someone could be mopping-up a chunk of these. are we about to finally ping above 30p and beyond?
audigger
07/4/2017
12:02
Start of the tax year and that balances last weeks trades as I see it.
jimmyloser
07/4/2017
11:48
Another 2.5 million shares at 27.5p - is someone building a holding?
richsawko
05/4/2017
07:22
New Hardman research note this morning http://hardmanandco.com/docs/defaultR08;source/company208;docs/allergyR08;therapeu cs‐documents/agy‐interimR08;resultsupdateR08; 5th‐april.pdf
jimmyloser
31/3/2017
12:55
WOW 2.5 MILLION SHARES JUST SOLD at 27p - what could this mean?
richsawko
30/3/2017
16:20
Good intraday recovery.Through 29p could be very bullish.
shauney2
29/3/2017
16:42
Director buying? These mm's smell news - lol I should bloody think so, it took long enough to motor.
jimmyloser
29/3/2017
16:39
Well we got some momentum! I missed that buying opportunity.
audigger
29/3/2017
11:07
Morning Short TV clip following results announcement today: www.fmp-tv.co.uk/company/allergy-therapeutics-investors-video-and-news/
oshy92
29/3/2017
09:04
Now it's starting to motor - must be related to presentation and people waking up!!
richsawko
29/3/2017
08:59
hTtp://tinyurl.com/lbamocb Broker finnCap, which rates the shares a 'buy' said that apart from a slightly lower than expected first half R&D charge, “which is likely to be timing related”, it will make no change to its full-year forecasts. “We retain a near term target price of 43p and point to the further upside that Pollinex Quattro (PQ) Grass programme in the US offers investors,” the broker said.
shauney2
29/3/2017
08:36
The cash burn will be dictated by the cost of their various trials so it will come in chunks. Their last raising was intended to cover the US grass opportunity so given the range finding trial didn't work as planned and the new opportunity in peanuts they will almost certainly need more cash as I doubt profitability in Europe will cover it. Of course there is always the possibility they may partner with a bigger outfit in the US so they would be a game changer. Selfishly I'd be happy with a further pull back in the short term readyy for my ISA top up!
audigger
29/3/2017
08:22
Yeah, I would have expected us to jump to high 20's at least based on these results. Maybe waiting for presentation at 9am!
richsawko
29/3/2017
08:12
They have lots of new products all needing funding...Peanuts...it is just a hunch. I am surprised at that lack of reaction to these results but as AuDigger stated This is AIM
jimmyloser
29/3/2017
08:00
I didn't see any description of drawdown of funds which could trigger raising more cash - did I miss this in the statement. Do we know what the cash burn rate is for the next year?
richsawko
29/3/2017
07:53
Rich, Perhaps they are keeping their powder dry for another RNS! The name of the game here now is to get that share price up before they raise more cash. impo/dyor.
jimmyloser
Chat Pages: 135  134  133  132  131  130  129  128  127  126  125  124  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20170430 16:34:35